WuXi AppTec, David Chang
WuXi AppTec brings in David Chang as CEO of its WuXi Advanced Therapies business unit, which is a contract development and manufacturing organization (CDMO) focused on cell and gene therapies.
Chang joins the company from Celgene, where he held the position of head of cell therapy global manufacturing. In this position, he specialized in the manufacture of chimeric antigen receptor (CAR)-T therapies.
Prior to Celgene, where he had worked for two years, Chang had spent time at some of the biggest names in the pharmaceutical industry – including five years at Roche, seven years at Genentech, and six years at Biogen.
For WuXi AppTec, the appointment of Chan coincides with the announcement of the launch of its closed process CAR-T platform.
WuXi AppTec’s investment in advanced therapeutics comes as the number of cell and gene therapies in the global pipeline continues to grow rapidly.
